Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 15/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.81 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.67 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292393 | 1.00 | HDAC2 (1.00) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL12425759 | 0.95 | HDAC8 (0.90) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL14244596 | 0.95 | HDAC8 (0.90) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL8250585 | 0.82 | HDAC2 (0.70) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL3292958 | 0.82 | HDAC2 (0.70) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL13067863 | 0.81 | HDAC2 (0.68) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL3291655 | 0.80 | HDAC2 (1.00) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL3291661 | 0.80 | HDAC2 (1.00) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL3290139 | 0.80 | HDAC2 (1.00) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL3292226 | 0.80 | HDAC2 (1.00) | HDAC2HDAC8HDAC3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896399-B1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA TAU IND FARMACEUTI (IT) | 2010-11-17 | — | — | EP | claimed |
| US-7728039-B2 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-06-01 | — | — | US | claimed |
| US-20080319082-A1 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-12-25 | — | — | US | claimed |
| EP-1896399-A1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-03-12 | — | — | EP | claimed |
| WO-2007000383-A1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-01-04 | — | — | WO | claimed |
| EP-1896399-B1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA TAU IND FARMACEUTI (IT) | 2010-11-17 | — | — | EP | disclosed |
| US-7728039-B2 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-06-01 | — | — | US | disclosed |
| US-20080319082-A1 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
| EP-1896399-A1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007000383-A1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319082-A1 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | VHL, ARNT, AHR | HDAC2 220/4885HDAC8 101/4885HDAC3 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.